Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis.

Praveen ThokalaPann Ei Hnynn SiMonica Hernandez AlavaAlessandro SassoThilo SchauflerMarco SoroJames Fotheringham

Published in: PharmacoEconomics (2023)

The cost effectiveness of difelikefalin in a range of scenarios could make it an important pharmacotherapy to address the high burden of disease and unmet need for treatments associated with CKD-aP in the UK.

Keyphrases

chronic kidney disease
end stage renal disease
transcription factor
healthcare
climate change
palliative care
quality improvement
smoking cessation
pain management
atopic dermatitis
chronic pain